title: Subgroup analyses of etanercept in pediatric patients with psoriasis.
authors.forename: Amy S
authors.initials: AS
authors.lastname: Paller
authors.forename: Lawrence F
authors.initials: LF
authors.lastname: Eichenfield
authors.forename: Richard G
authors.initials: RG
authors.lastname: Langley
authors.forename: Craig L
authors.initials: CL
authors.lastname: Leonardi
authors.forename: Elaine C
authors.initials: EC
authors.lastname: Siegfried
authors.forename: Kara
authors.initials: K
authors.lastname: Creamer
authors.forename: Gregory
authors.initials: G
authors.lastname: Kricorian
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept